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Monocyte adhesionPrevious studies indicate a novel role for the osteoclast-associated receptor (OSCAR) in oxidative
stress-mediated atherogenesis. However, the functional role of OSCAR in endothelial cells is unknown.
Here we characterized OSCAR signaling in human endothelial cells using a proteomic approach. OSCAR
was either overexpressed or silenced, and the functional effects were assessed by an in-depth proteomic
study using stable isotope labeling with amino acids in cell culture (SILAC). Reduction of complexity using
subcellular protein fractions from the membrane, the cytosol, and the nucleus of human endothelial cells en-
abled the detection of 4975 unique proteins. Of these proteins, OSCAR overexpression regulated 145 and
OSCAR silencing regulated 110. These proteins were mainly involved in cellular proliferation, inﬂammatory
response and cell-to-cell signaling. Interestingly, OSCAR modulation reciprocally regulated signal transducer
and activator of transcription 1 (STAT1) and 3 (STAT3). Thus, STAT1 and several interferon-induced proteins
showed a clear inverse correlation to OSCAR expression, which was further veriﬁed by Western blot analysis.
In contrast, it was found that OSCAR overexpression activated STAT3. Furthermore, OSCAR overexpression in-
creased proteins involved in cell adhesion, which correlated with an increased adhesion of monocytes to the
endothelium after OSCAR overexpression. In conclusion, using a comprehensive proteomic approach, endo-
thelial cell-derived OSCAR was found to be involved in the STAT signaling pathway and to affect monocyte
adhesion. This indicates a novel role of OSCAR in the vascular-immune cross-talk.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
During the last decade, the osteoclast-associated receptor
(OSCAR) has been identiﬁed and characterized as an important
osteoimmunological mediator [1,2]. In bone, OSCAR expression is
highly conserved across different species. OSCAR serves as a co-
stimulatory molecule for osteoclast differentiation and is involved in
the positive feedback circuit of the immunoreceptor nuclear factor of
activated T cells (NFAT)c1 pathway [3]. Furthermore, OSCAR provides
co-stimulatory signals required for receptor activator of nuclear factor
kappa-B ligand (RANKL)-mediated activation of calcium signaling [1].
In humans, OSCAR was initially detected in macrophages, monocytes
andmonocyte-derived dendritic cells, where the receptor modulates
the response of the innate and adaptive immune systems bycs, UFZ, Helmholtz-Center for
zig, Germany. Tel.: +49 341
NC-ND license. promoting cell activation and maturation, antigen presentation,
and pro-inﬂammatory circuits [4–6]. Recently, OSCAR was identiﬁed
as a receptor for collagen [7]. Knowledge about the role of OSCAR for
human disease is limited to reports on skeletal and joint disorders
[8,9]. Previously, we identiﬁed OSCAR in vascular endothelial cells and
identiﬁed a potential role in oxidative-stress mediated atherogenesis.
In human endothelial cells, OSCAR is regulated by oxidized low-
density lipoproteins in a calcium/NFAT-dependent manner [10]. How-
ever, the functional role of endothelial cell-derived OSCAR and involved
signaling pathways are unknown.
To elucidate changes in the complex protein network in response
to molecular effects like knock-out or knock-in, proteome-wide
quantitative proteomics was used to detect regulated and thus func-
tionally relevant proteins [11]. Stable isotope labeling by amino
acids in cell culture (SILAC) uses metabolic labeling by isotopically la-
beled amino acid, which allows for a highly accurate quantitative
comparison of changes in protein expression based on mass spectro-
metric measurement of peptides [12].
Here, we combined regulation of gene expression by silencing and
overexpression with cell fractionation, SILAC, and proteome-wide
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according to related biological processes and molecular functions to
reveal the involved cellular processes inﬂuenced by OSCAR in
human endothelial cells.
2. Materials and methods
2.1. SILAC sample preparation
Four biological replicates were prepared for SILAC experiments of
OSCAR silencing and of OSCAR overexpression. Endothelial cells
were labeled by cultivation in a SILAC-DMEM-ﬂex-kit-medium
(Invitrogen, Karlsruhe, Germany) containing stable isotope labeled
((U-13C6, 15N4)-L-arginine, (U-13C6)-L-lysine; heavy) or unlabeled
arginine/lysine (light) for at least seven days before transfection. Be-
forehand, it was determined to allow for at least seven cell deviations
to ensure at least 95% incorporation of heavy amino acids. The cells of
the biological replicates were washed and lysed with 6 M urea, 2 M
thiourea and protease inhibitor (Roche, Mannheim, Germany) to
get whole cell extracts as described elsewhere [12]. For two of the
four replicates, fractions of nuclei, membrane and cytoplasm were
prepared using the ProteoExtract Subcellular Proteome Extraction
Kit (Calbiochem, Darmstadt, Germany). Protein concentrations
were determined by BCA protein assay (Pierce, Rockford, IL, USA).
2.2. Construction of plasmids encoding fusion proteins
All vector plasmids were obtained from Invitrogen. The coding
cDNA sequence of human OSCAR (NM_206818) was ampliﬁed by
PCR and cloned into the pCR-II-TOPO vector (Invitrogen, Darmstadt,
Germany). Stop codon was deleted by PCR and cDNA was cloned in
the same vector. This vector subsequently cloned into the pcDNA4/
TO/myc-HisTM vector (Invitrogen, Darmstadt, Germany), resulting in
pcDNA4/TO/OSCAR-myc-His plasmid. The integrity of each construct
was conﬁrmed by DNA sequencing.
2.3. Transfection and overexpression of fusion proteins
Humanmicrovascular endothelial cells (HMEC)-1 (21) were kind-
ly provided by Francisco J. Candal [13] and cultured in endothelial cell
growth medium 2 (PromoCell, Heidelberg, Germany). Since primary
cultures of human endothelial cells can only be transfected at very
low efﬁciency levels, HMEC-1 cells already labeled with either
heavy or light amino acids (described in ‘SILAC sample preparation’)
were transfected with the pcDNA4/TO/OSCAR-myc-His plasmid or
pcDNA4/TO/LacZ-myc-His plasmid as control using Fugene HD trans-
fection Reagent (Roche, Mannheim, Germany). After 6 h, the super-
natant was replaced by fresh medium. After 48 h proteins were
lysed and processed for SILAC measurements.
2.4. Transfection of siRNA
HMEC-1 cells were treated with either siRNA against OSCAR
(ON-TARGETplus SMART-pool, L-012922-00-0010) or non-target
negative control (Dharmacon RNAi Technologies, Chicago, IL, USA),
respectively. Transfection of 50 nM siRNAs was performed using
DharmaFECT-1 transfection reagent (Dharmacon RNAi Technologies,
Chicago, IL, USA). After 48 h proteins were lysed and processed for
SILAC measurements.
2.5. Western blot analysis
Western blots were performed as described previously using the
parameters given in the Supplementary Table 1 [10]. Quantiﬁcation
of protein expression was performed using ImageJ software.2.6. ELISA
Cells were lysed in 20 mM Tris–HCl (pH 7.4), 1% SDS and protease
inhibitor (Roche, Mannheim, Germany). OSCAR concentration was
measured in 1 μg of whole-cell lysate using the ELISA kit for
Osteoclast-associated Receptor from Uscn Life Science Inc. (Wuhan,
China).
2.7. RNA preparation and real-time PCR
Total RNA from cell culture was isolated using the High Pure RNA
Isolation kit (Roche, Mannheim, Germany). The mRNA expression
was determined by SYBR green-based real-time PCR reactions as de-
scribed previously [10]. Expression was normalized to β-actin. The re-
sults were calculated using the delta CT method and are presented as
an x-fold increase relative to control.
2.8. Monocyte adhesion
HMEC-1 cells were transfected with pcDNA4/TO/OSCAR-myc-His
or pcDNA4/TO/LacZ-myc-His as a control. THP-1 cells were labeled
with CellTracker-green (Invitrogen, Darmstadt, Germany). Forty-
eight hours after transfection 300,000 labeled THP-1 cells were
added to the endothelial cells and incubated for 15 min. HMEC-1
cells were stimulated with 100 μg/ml oxLDL for 3 h prior to THP-1
addition. After two washing steps, attached monocytes were deter-
mined by ﬂuorescence measurement using the FluoStar-Optima
(BMG, Offenburg, Germany).
2.9. Protein separation, liquid chromatography/tandem mass spectrome-
try and data analysis
Equimolar amounts of each of the protein lysates (heavy-labeled:
light-labeled) were mixed prior to separation by 1D-SDS-PAGE and
prepared for LC-MS analyses [14]. Protein mixtures (in total 30 μg)
were precipitated with acetone and dissolved in 0.5 M Tris–HCl buff-
er pH 6.8 containing 40% SDS (v/v), 20% (v/v) glycerol, 2% (v/v)
bromo phenol-blue, and 10% (v/v) 2-mercaptoethanol. After heating
for 5 min at 60 °C, a 1D-SDS-PAGE (12% resolving gel, 4% stacking
gel) was carried out according to Laemmli [15]. Gel lanes were cut
into ﬁve pieces; proteins were digested with trypsin and extracted
peptides were measured by nano-HPLC/nano-ESI-MS/MS by an on-
line reversed-phase nanoscale liquid chromatography tandem mass
spectrometry on a NanoAcquity UPLC system (Waters Corporation,
Milford, MA, USA). This UPLC system was connected to an LTQ-
Orbitrap XL ETD (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
equipped with a nano-ESI source (TriVersaNanoMate, Advion, Itha-
ca, NY, USA) as described earlier [16] using a 4 h acetonitrile gradient
(2–85% phase B) with a ﬂow rate of 300 nl/min. MS analysis was
performed in positive ion mode using a continuous scanning of elut-
ed peptide ions in a mass range m/z 350–1600. The system automat-
ically switched to CID-MS/MS mode on the six most intense ions with
an intensity of more than 3000 counts and a charge state higher than
1. For protein identiﬁcation and relative quantiﬁcation MaxQuant soft-
ware (version 1.1.1.25, www.maxquant.org) with default parameter
settings was used [17]. Database searchwas carried out by the integrat-
ed search engine Andromeda against the IPI human database version
3.68. A peptide FDR speciﬁcation of 0.01 was applied, whereas the pre-
cursormass tolerancewas set to 10 ppm, and reﬁned duringMaxQuant
processing as described [18]. Oxidation (methionine), acetylation (pro-
tein N-termini) and deamination (glutamine) were used as variable
modiﬁcations. Carbamidomethylation (cysteine) was set as ﬁxed mod-
iﬁcation and amaximum of two tryptic missed cleavageswere allowed.
MaxQuant combines proteins into one group whenever the set of iden-
tiﬁed peptides for one protein is equal to a set of peptides from another
protein. Those shared peptides are then associated with the groupwith
Fig. 1. Schematic overview of proteomic procedure. Endothelial cells (HMEC-1) were labeled by cultivation in a SILAC medium containing stable isotope labeled arginine/lysine
(13C, 15N; heavy) or unlabeled arginine/lysine (12C, 14N; light) and OSCAR was silenced or overexpressed for 48 h. A three-dimensional separation procedure was applied, in
which proteins were separated based on (1) cellular localization to reduce complexity, (2) on molecular weight (SDS-PAGE), and (3) proteolytic peptides were separated according
to their hydrophobicity (reverse-phase HPLC) and quantiﬁed by gel LC-MS/MS analyses.
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Nevertheless they remain in all protein groups where they occur [18].
Due to this fact we used a minimum of two unique peptides for a dis-
tinct peptide assignment as well as for an accurate protein identiﬁca-
tion and quantiﬁcation. Of each remaining protein groupwhich were
undistinguishable by the identiﬁed peptides representative entries
one protein was selected for further pathway analysis. Raw ﬁles of
the LC-MS/MS analyses are available on Tranche ﬁle sharing server
(https://proteomecommons.org/tranche/).
2.10. Clustering of proteins according to biological function and involved
transcription factors
Proteins, which were differentially expressed with a fold change
±0.5 in the replicates were considered to be regulated and were
used for a cluster analysis with the web-delivered application ‘Inge-
nuity Pathway Analysis’ (IPA; ‘Winter Release (2011)’, www.
ingenuity.com, Ingenuity Systems, Redwood City, CA, USA). Regulat-
ed proteins of either the silencing or the overexpression experiments
were mapped to their corresponding gene object in the Ingenuity
Pathways Knowledge Base and further used for generating biological
networks, biological functions and involved transcription factor
were inferred. Thereby, the overexpression and silencing experi-
ments were treated independently. The results of the tool ‘functional
analysis’were used to extract biological functions which were signif-
icantly altered in the data sets. Biological networks with a size of no
more than 35 genes are built upon generating interactions between
the so called ‘focus genes’ and all other genes stored in the knowl-
edge base. The score for each network is calculated according to
the set of the user's signiﬁcant genes. It indicates the likelihood of
the genes in a network being found together due to random chance
and is derived from a p‐value calculated by Fisher's exact test
which is then further used for ranking the functions according their
signiﬁcance within this network.
Additionally ‘transcription factor analysis’ was used to identify
transcription factors that are activated or inhibited within the
dataset with a p-valueb0.05. This analysis uses literature-based ef-
fects between transcription factors and target genes compiled in
the Ingenuity Knowledge Base. Targets in the dataset are examinedand compared according to the targets' direction of change to the lit-
erature ﬁndings. IPA uses the z-score algorithm to make predictions.
If the direction of change is consistent IPA predicts that the transcrip-
tion factor is more active (z-score is≥2) and if it is more inconsistent
the transcription factor is less active in the experimental dataset
(z-score≤−2). No prediction is made when there is no clear pattern
related to the literature.
2.11. Statistical analysis
Data are given as means±s.d., and n indicates the number of inde-
pendent experiments. Statistical analyses were performed using a
one-way ANOVA with Bonferroni's post hoc test, single group com-
parisons using a Student's t test or as described above. A value of
pb0.05 was considered statistically signiﬁcant.
3. Results
3.1. Modulation of OSCAR expression
Todetermine cellular functions of OSCAR in human endothelial cells,
we used either silencing or overexpression in combination with com-
parative proteomics and functional cluster analysis of regulated pro-
teins (Fig. 1). Overexpression caused a 1.5-fold OSCAR induction
(155.0%±0.1%), whereas the transfection of the LacZ control vector
did not affect OSCAR expression as assessed by ELISA (Fig. 2A). The
use of siRNA technology led to a 44.0%±0.2% decrease in OSCAR ex-
pression compared to endothelial cells treated with scrambled siRNA
(Fig. 2A). These data were conﬁrmed by Western blot (Fig. 2B; fold in-
crease to control (100%): OSCAR overexpression 207%±47%; OSCAR si-
lencing 19%±5%) and real‐time PCR (Fig. 2C). None of the tested
conditions altered cell morphology and cell growth.
3.2. Determination of differentially expressed and affected proteins by
quantitative proteomics
In order to elucidate the function of endothelial-derived OSCAR
we applied a three-dimensional separation procedure, in which pro-
teins were ﬁrst separated based on cellular localization to reduce
Fig. 2. Validation of OSCAR modulation. (A) OSCAR overexpression and silencing was
measured by ELISA (n=4). (B) Western blot shows the induction of OSCAR by
overexpression (OSCAR) and suppression by siRNA (si OSCAR). LacZ and a scramble
control (scr con) served as controls, respectively. β-actin was used as loading control.
Three independent experiments are shown. Numbers indicate the fold increase.
*Pb0.05 vs. corresponding control. (C) OSCAR mRNA expression. n=3. Data present
the mean±s.d. *Pb0.05.
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proteolytic peptides were separated according to their hydrophobici-
ty (reverse-phase HPLC).
To provide a comprehensive and reproducible analysis, we used
four biological replicates, where replicates 1 and 2 were measured
by a standard gel LC-MS analyses and replicates 3 and 4 were
subjected to a subcellular fractionation prior gel LC-MS analyses.
Using this data in combination with the three-dimensional separation
procedure we were able to identify a total of 4975 unique proteins
with a false discovery rate (FDR) of b1%, of which 2870 and 2105 pro-
teins were quantiﬁed at least in two replicates based on at least two
pairs of SILAC peptides in the overexpression or silencing experi-
ments, respectively (Supplementary Tables 2 and 3).
As a beneﬁt of the cellular fractionation 81, 63 and 117 proteins
were solely detected in the nuclear, cytosolic or membrane fraction
and also not in the whole cell lysates of the OSCAR overexpression
experiment (Fig. 3A). For the silencing experiment 41, 63, and 189 pro-
teins were exclusively quantiﬁed in the nuclear, cytosolic or membranefraction (Fig. 3C). In summary, the reduction of complexity using sub-
cellular fractionation increased our proteome coverage in case of the
OSCAR overexpression analysis for about 23% (including overlapping
proteins between fractions) and 17% for OSCAR silencing, respectively
(Figs. 3A, B). Furthermore the log2-ratios (OSCAR overexpression vs.
control and OSCAR silencing vs. control) of protein expressions were
found to be normally distributed (Figs. 3B, D).
3.3. Differential expression of proteins caused by OSCAR overexpression
In response to OSCAR overexpression the expression of 145 pro-
teins (5.1% of the quantiﬁed proteins) was determined to be signiﬁ-
cantly up or down‐regulated by more than 50% (Supplementary
Table 4a, Fig. 3B). Using the IPA-software, ten networks with highly
signiﬁcant scores between 24 and 46 were identiﬁed (Supplementary
Table 5a). According to the enrichment analysis, the six most signiﬁ-
cant biological functions for each network were: cellular growth and
proliferation (score 45, 24 proteins), inﬂammatory response (score
42, 22 proteins), cellular development (score 38, 21 proteins), con-
nective development and function (score 36, 20 proteins), metabolic
disease (score 31, 18 proteins) and cell-to-cell signaling and interac-
tion (score 28, 18 proteins) (Supplementary Table 5c).
3.4. Differentially expressed proteins in response to OSCAR silencing
Of the 2105 proteins which have been quantiﬁed in the silencing
experiment, 110 proteins (5.2%) were determined to be differentially
expressed (Supplementary Table 4b, Fig. 3D). Following OSCAR si-
lencing, the most affected functions issued by IPA were: cellular
growth and proliferation (score 48, 24 proteins), inﬂammatory re-
sponse (score 31, 16 proteins), cell death (score 27, 15 proteins), en-
ergy production (score 26, 14 proteins) and cell-to-cell signaling and
interaction (score 22, 13 proteins) (Supplementary Table 5b and d).
3.5. Transcription factor analysis
Next, IPA ‘transcription factor analysis’ was used to identify tran-
scription factors that were responsible for altered gene expression
caused by OSCAR overexpression or silencing. N-Myc was predicted
to be the most relevant transcription factor with p-values of
4.19×10−13 and 3.31×10−10, respectively. In OSCAR silenced cells
N-Myc was predicted based on 15 altered genes, whereas in OSCAR
overexpression, the expression of 16 differentially expressed proteins
was controlled by N-Myc (Supplementary Table 5e, f). These ﬁndings
were supported by Western blot analysis demonstrating slightly re-
duced N-Myc expression by OSCAR overexpression, whereas OSCAR
silencing tremendously induced N-Myc expression (Fig. 4C). In the
transcriptional networks, most of the affected genes are involved in
cell adhesion (e.g. integrin β1, ﬁbronectin, tissue growth factor) or
cellular component organization (e.g. elongation factor 2, caveolin 1).
3.6. OSCAR is involved in STAT signaling pathway
Expression of STAT1 (log2 ratio (OSCAR regulation/control)
−0.70±0.23) as well as eight IFN-inducible proteins was suppressed
by OSCAR overexpression (Fig. 4A, Table 1). To conﬁrm this ﬁnding,
we performed Western blot analysis of interferon-induced GTP-
binding protein Mx1 and total or phosphorylated STAT1 and STAT3. In
agreement with the SILAC data, OSCAR overexpression caused signiﬁ-
cant reduction of Mx1 and STAT1 expression, whereas OSCAR silencing
inducedMx1 and STAT1 protein expression aswell as STAT1 activation,
as evident from its markedly increased phosphorylation at Tyr701
(Figs. 4B, C). In line with these ﬁndings, MHC class II transactivator
CIITA, a known downstream target of STAT1, was repressed by OSCAR
overexpression and induced by OSCAR silencing (Fig. 4C). On the
other hand, overexpression of OSCAR promoted STAT3 expression as
Fig. 3. Protein log2 ratios (OSCAR regulation vs. control) determined by the analysis of cell lysates and subcellular fractions were found to be normally distributed in response to
OSCAR overexpression and OSCAR silencing. (A, C) Pie-charts display the percentage of quantiﬁed proteins in the whole cell lysate and in subcellular fractions in (A) OSCAR
overexpression and (C) OSCAR silencing experiment. Increase of protein identiﬁcation and quantiﬁcation due to fractionation into cytosolic, membrane and nuclear fractions is vi-
sualized in the dedicated bar-chart (>1 represents the percentage of proteins found in more than 1 fraction). (B, D) Representative histograms show the normal distribution of
protein ratios as well as the portion of regulated from the whole cell lysate of (B) OSCAR overexpression and (D) OSCAR silencing experiment.
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inhibitor of activated STAT3 (PIAS3), whereas OSCAR silencing reduced
STAT3 and PIAS3 levels (Figs. 4B, C). Thus, our results suggest that
STAT1 and STAT3 are reciprocally activated by OSCAR.
3.7. OSCAR regulates cell-adhesion mediated signaling as well as mono-
cyte adhesion
OSCAR overexpression increased several proteins which are in-
volved in the cell-adhesion-mediated signaling up to 2.1-fold
(Fig. 5A, log2 ratio (OSCAR regulation/control): vinculin 2.1±0.1,Fig. 4. Impact of OSCAR on STAT signaling pathway. OSCAR was overexpressed (OSCAR)
(A) Regulation of interferon-induced proteins and STAT1. Proteomic results are represent
STAT1 (pSTAT1, Tyr 701), STAT3 and phosphorylated (activated) STAT3 (pSTAT3, Tyr 705)
N-Myc, CIITA, and PIAS3 expression analyzed using Western blot. ISG15, interferon-induce
GTP binding protein; CIITA, class II, major histocompatibility complex, transactivator; PIAS3ﬁlamin A 1.6±1.2, catenin α1 1.0±0.3), whereas OSCAR silencing
caused a decrease of cell-adhesion proteins (log2 ratio: ICAM-1
−1.2±0.4, PECAM-1−1.0±0.1, integrin β1−0.8±0.3, Fig. 5A). Rep-
resentative, the expression of integrin β1 (overexpression 0.8±1.2,
silencing −0.8±0.3) and ICAM-1 was conﬁrmed by Western blot
(Figs. 5B–D). ICAM-1 protein expression increased by OSCAR
overexpression (Fig. 5C), whereas OSCAR silencing caused ICAM-1 re-
pression (Fig. 5D). The functional relevance of these ﬁndings was con-
ﬁrmed by assessing monocyte adhesion. While monocyte adhesion to
OSCAR-silenced endothelial cell did not alter (data not shown);
OSCAR overexpression signiﬁcantly increased monocyte adhesion toor silenced (si OSCAR) for 48 h. LacZ or scramble siRNA (scr con) served as control.
ed as Log2 (heavy/light ratio) and mean±s.d. (B) STAT1, phosphorylated (activated)
expression determined by Western blot. GAPDH served as loading control. (C) Mx1,
d 15 kDa protein; IFI56, interferon-induced 56 kDa protein; Mx1, interferon-induced
, protein inhibitor of activated STAT3.
Table 1
Regulated pathways by either OSCAR overexpression or silencing.
IPI-ID Protein name Overexpression Silencing
Integrin signalling pathway
IPI00215920 ADP-ribosylation factor 6 −0.8±0.3 #
IPI00215918 ADP-ribosylation factor 4 −0.8±0.2 −0.3±0.1
IPI00215914 ADP-ribosylation factor 1 −0.8±0.1 −0.1±0.1
IPI00013981 Proto-oncogene tyrosine protein kinase Yes −0.6±0.0 #
IPI00009236 Caveolin 0.2±0.0 −1.1±0.1
IPI00855785 Fibronectin 0.3±0.3 4.8±0.1
IPI00003269 β-Actin-like protein 2 0.4±0.0 −0.7±0.0
IPI00021440 Actin, cytoplasmic 2 0.5±0.0 −0.9±0.0
IPI00217563 Integrin β1 0.8±1.2 −0.8±0.3
IPI00333541 Filamin-A 1.7±1.2 −0.4±0.2
IPI00013808 α-Actinin-4 1.8±0.9 −0.3±0.1
IPI00307162 Vinculin 2.1±0.1 −0.1±0.1
IPI00306604 Integrin αV 1.0±1.8 #
IPI00290043 Integrin αIII 0.2±0.2 −0.8±0.5
Cell adhesion
IPI00016334 Cell surface glycoprotein MUC18 0.1±0.2 −1.0±0.5
IPI00015102 Activated leukocyte cell adhesion molecule 0.0±0.2 −0.7±0.1
IPI00217563 Integrin β1 0.8±1.2 −0.8±0.3
IPI00215997 Leukocyte antigen MIC3 0.3±0.1 −0.6±0.3
IPI00008494 Intercellular adhesion molecule 1 # −1.2±0.4
IPI00009477 Intercellular adhesion molecule 2 # −1.0±0.4
IPI00307162 Vinculin 2.1±0.1 −0.1±0.1
IPI00215948 Catenin α1 1.0±0.3 −0.3±0.2
IPI00013808 α-Actinin-4 1.8±0.9 −0.3±0.1
IPI00295618 PECAM-1 0.1±0.2 −1.0±0.1
IPI00045839 Growth suppressor 1 0.0±0.0 −0.7±0.1
IPI00017292 Catenin β1 0.9±1.4 −0.7±0.0
IPI00021440 Actin, cytoplasmic 2 0.5±0.0 −0.9±0.0
IPI00333541 Filamin-A 1.6±1.2 −0.4±0.2
IPI00306604 Integrin αV 1.0±1.8 #
IPI00305064 GP90 lymphocyte adhesion receptor 0.5±0.2 −0.4±0.0
Interferon signaling
IPI00167949 Interferon-induced GTP-binding
protein Mx1 −2.8±0.1 1.7±2.3
IPI00018300 Interferon-induced 56 kDa protein −1.9±0.1 0.2±0.1
IPI00008613 Interferon-induced 35 kDa protein −0.9±0.1 0.2±0.4
IPI00375631 Interferon-induced 15 kDa protein −2.2±0.1 0.6±1.0
IPI00019463 Interferon-induced, double-stranded RNA-activated protein kinase −0.7±0.0 0.5±0.2
IPI00024254 Interferon-induced 60 kDa protein −2.2±0.1 #
IPI00303726 Interferon-induced transmembrane protein 3 −0.8±0.3 #
Data are represented as log2 (heavy/light ratio) and mean±s.d.; n=4; #, no value; IPI, international protein index.
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with the effect of oxidized low-density lipoprotein (oxLDL) (Fig. 5D).
The potential functions of OSCAR in human endothelial cells are sum-
marized in Fig. 6.
4. Discussion
OSCAR, a receptor initially characterized as co-stimulatory regula-
tor of osteoclast and dendritic cell function, was recently identiﬁed as
a novel receptor on vascular endothelial cells that is regulated by
oxLDL in a calcium/NFAT-dependent manner [10]. In order to explore
the signaling pathways inﬂuenced by OSCAR in endothelial cells, we
analyzed the effects of OSCAR overexpression and silencing on global
protein expression by quantitative proteomics.
In vascular endothelial cells, we found an inverse regulation of
STAT1 and STAT3, with activation of STAT3 occurring with OSCAR
overexpression, and activation of STAT1 occurring with OSCAR silenc-
ing. Among others such as paired Ig-like receptor A, platelet glycopro-
tein VI or leucocyte Ig-like receptor, OSCAR is one of the known
receptors that do interact with the immunoreceptor tyrosine-based
activation motif (ITAM)-containing adaptor molecule Fc receptor
γ-chain [19]. Thus, regulation of STAT signaling by cross-talks to
ITAM-dependent pathways [20] might be directly linked to and con-
trolled by OSCAR. It has been shown that strong activation of ITAM
signaling suppresses JAK/STAT-signaling. Conversely, low-level basalactivation of ITAM-signaling can result in an increased tyrosine or
serine phosphorylation of STAT1 and thus enhanced transcriptional
activity [21]. In this context, it is interesting to note that in agreement
with STAT1 activation in endothelial cells, caused by silencing of
OSCAR, we observed a reduction of several IFN-induced proteins
known to lie downstream of STAT1.
In osteoclasts, OSCAR itself is controlled by both, the STAT3 and
the STAT1 pathways, either by the protein inhibitor of activated
STAT3 (PIAS3) [22] or by IFN-γ induction of the MHC class II
transactivator CIITA, which diminishes OSCAR expression in osteo-
clasts [23,24]. Thus, we postulate the potential existence of a feedback
loop in endothelial cells in which STAT1 and OSCAR regulate each
other by a strong ITAM activation by OSCAR, which could result in a
reduced activation of STAT1 and thus ﬁnally in a reduced activity of
the OSCAR suppressing CIITA.
STAT1 and STAT3 are well-known antagonistic transcription factors
which are activated by the opposing cytokines IFN-γ and interleukin
(IL)-10, respectively [25]. A balanced expression/activation of STAT1
and STAT3 is important to modulate the responses to cytokines and
growth factors such as macrophage activation (activation by STAT1 vs.
inhibition by STAT3), cell proliferation (suppression by STAT1 vs. pro-
motion by STAT3), and Th cell differentiation (Th 1 responses promoted
by STAT1, Th 17 responses supported by STAT3) [26].
Additionally, in endothelial cells, the balance of STAT1 and STAT3 is
critical, since coordinated STAT1 activation and STAT3 inactivation are
Fig. 5. Impact of OSCAR on cell-adhesion mediated signaling. OSCAR was overexpressed (OSCAR) or silenced (si OSCAR) for 48 h. LacZ or scramble siRNA (scr con) served as control.
(A) Regulation of proteins which belong to the cell-adhesion pathway. Proteomic results are represented as Log2 (heavy/light ratio) and mean±s.d. (B) Integrin β1 protein expres-
sion shown by Western blot. GAPDH served as loading control. (C, D) ICAM-1 protein expression. Western blots from 3 independent experiments are shown at the top. GAPDH
served as loading control. The quantiﬁcation is summarized in the corresponding bar graphs (n=3). *Pb0.05 vs. corresponding control. (D) Monocyte adhesion to the endothelium.
LacZ served as control. THP1 adhesion was measured with and without 3 h pre-stimulation oxidized LDL (oxLDL, 100 μg/ml). n=4; *Pb0.05. Data are represented as mean±s.d.
ACTB, Actin; ACTN, actinin; ALCAM, activated leukocyte cell adhesion molecule, CTNNA1, catenin α1; CTNNB, catenin â1; MCAM, cell surface glycoprotein MUC18; FLNA, ﬁlamin A;
GROS1, growth suppressor 1; ITGA5, integrin αV; ITGB1, integrin â1; ICAM-1, intracellular adhesion molecule 1; ICAM-2, intracellular adhesion molecule 2; CD9, leucocyte antigen
MIC3; PECAM-1, platelet endothelial cell adhesion molecule; VCL, vinculin.
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cytokine-activated GTP cyclohydrolase [27]. Based on the reciprocal re-
sponses of STAT1 and STAT3 observed in our experiments, we suggest
that in human endothelial cells, the cytokine-dependent balanced acti-
vation of these two STAT proteins may be mediated by OSCAR.
STAT proteins have also been implicated in the development and
progression of cardiovascular diseases. STATs are activated in atheroma-
tous plaques andmay be involved in the stimulation of cells by vascular
endothelial growth factor, hepatocyte growth factor and angiotensin II.
STATs cause thrombogenesis due to the regulation of eithermajor histo-
compatibility complex class II molecules or phospholipase A2 [28]. Both,
STAT1 and especially STAT3, play important roles in vascular remod-
eling [28] and wound re-epithelialization [29]. Additionally, it has
been shown that STAT3 increased resistance to apoptosis in pulmo-
nary artery endothelial cells [30] and prevented endothelial cell dys-
function and inﬂammation induced by chronic alcohol intake [31].
This is consistent with our previous ﬁndings of reduced apoptosis
and increased cell viability upon OSCAR activation in human endo-
thelial cells [10], which in turn might be mediated by the STAT3 ac-
tivation observed in the current experiments.Interestingly, N-Myc, which is induced by IFN-γ via STAT1 [32],
was determined to be the most affected transcription factor by
OSCAR silencing and overexpression. N-Myc limits cell adhesion to
the extracellular matrix and promotes cell migration by down-
regulating integrin [32–35], which strengthens our observation of
integrin β1 repression by OSCAR silencing. A cluster of proteins relat-
ed to cell adhesion and cell adhesion-mediated signalingwas altered by
OSCAR overexpression or silencing.We observed an induction of vascu-
lar adhesion molecules such as integrins, ICAMs and PECAM by OSCAR
overexpression, which are established markers in the development
and progression of atherosclerosis [36]. In accordance with these ﬁnd-
ings, we found an increased monocyte adhesion to the endothelium in
response to OSCAR overexpression. Interestingly, activation of OSCAR
on dendritic cells increases the production of monocyte chemo-
attractant protein 1, which is involved in the recruitment of leukocytes
to sites of inﬂammation [37]. In addition, aggregation of OSCAR on
humanmonocytes triggers intracellular calcium release and is responsi-
ble for the sustained secretion of high levels of IL-8, which is an
established factor for the induction of monocyte adhesion to the endo-
thelium [38,39]. Based on this data, OSCARmaymodulatemonocyte cell
Fig. 6. Potential role of OSCAR in STAT signaling and cell adhesion processes — a work-
ing model. The STAT1 pathway is activated by OSCAR silencing, whereas the STAT3
pathway activation is induced by OSCAR overexpression. Activation of STAT1 induces,
CIITA, IFN-inducible genes and activates the transcription factor N-myc, which could
inhibit integrin. OSCAR overexpression induces cell adhesion molecules (like
ICAM-1) and thereby may promote monocyte adhesion to the endothelium. ICAM, in-
tracellular adhesion molecule; ITAM1, immunoreceptor tyrosine-based activation
motif containing adaptor molecules; oxLDL, oxidized low density lipoprotein; PIAS3;
protein inhibitor of activated STAT3; CIITA, class II, major histocompatibility complex,
transactivator. This model reﬂects the data from this and other studies.
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tionally, FCRγ has been shown to play a role in the adhesion of mono-
cytes [40] and development of atherosclerosis [41] which might be
regulated by the interaction with OSCAR.
Binding of endothelial cell-derived integrin to extracellular-matrix
components is an essential step to initiate intracellular signaling. Re-
cently, OSCAR was identiﬁed as a receptor for extracellular matrix
collagen. Binding of OSCAR to collagen I–III motifs caused enhanced
osteoclastogenesis [7]. Thus, collagen bound to endothelial OSCAR
may increase platelet-adhesion to the endothelium via interaction
with induced integrin β1 and platelet glycoprotein VI which increases
the risk of thrombus formation [7,33].
Nevertheless, our study has potential limitations: (1) The usage
of HMEC-1 cells may not represent the full phenotype of arterial en-
dothelial cells. However, HMEC-1 cells are commonly used as an in
vitro model for human arterial endothelial cells [10,42–44] particu-
larly to overcome the disadvantages of natural donor variation
when employing primary cells. (2) Even though cell fractionation,
gel electrophoresis and reverse phased chromatography were suc-
cessively used to reduce the sample complexity, the high number
of 2870 (OSCAR overexpression) and 2105 (OSCAR knockdown)
quantiﬁed proteins still does not cover the whole proteome. This in-
completeness as well as the missing information about the protein
activation triggered by phosphorylation, as shown for STATs, or
other posttranslational modiﬁcations might result in OSCAR effects
which remain to be unobserved.In conclusion, we provide evidence for an active role of OSCAR in
vascular-immune cell cross-talks by affecting STAT signaling as well
as cell adhesion processes.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.yjmcc.2012.09.003.
Disclosures
None declared.
Acknowledgments
The authors would like to thank Nicole Pacyna and Jacqueline
Kobelt for excellent technical assistance.
This work was supported by the Deutsche Forschungsgemeinschaft
grant GO1801/4-1 (to C.G. and L.C.H.), a European Calciﬁed
Tissue Society Postdoctoral fellowship (to C.G) and the Deutsche
Forschungsgemeinschaft Transregio-67, projects B2 (to L.C.H.) and Z4
(to M.v.B).
References
[1] Nemeth K, Schoppet M, Al-Fakhri N, Helas S, Jessberger R, Hofbauer LC, et al. The
role of osteoclast-associated receptor in osteoimmunology. J Immunol 2011;186:
13-8.
[2] Takayanagi H.Mechanistic insight into osteoclast differentiation in osteoimmunology.
J Mol Med 2005;83:170-9.
[3] Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H. Contribution of nuclear
factor of activated T cells c1 to the transcriptional control of immunoreceptor
osteoclast-associated receptor but not triggering receptor expressed by myeloid
cells-2 during osteoclastogenesis. J Biol Chem 2005;280:32905-13.
[4] Regis G, Pensa S, Boselli D, Novelli F, Poli V. Ups and downs: the STAT1:STAT3 see-
saw of interferon and gp130 receptor signalling. Semin Cell Dev Biol 2008;19:
351-9.
[5] Kim K, Lee J, Kim JH, Jin HM, Zhou B, Lee SY, et al. Protein inhibitor of activated
STAT3 modulates osteoclastogenesis by down-regulation of NFATc1 and
osteoclast-associated receptor. J Immunol 2007;178:5588-94.
[6] Krause A, Scaletta N, Ji JD, Ivashkiv LB. Rheumatoid arthritis synoviocyte survival
is dependent on Stat3. J Immunol 2002;169:6610-6.
[7] Barrow AD, Raynal N, Andersen TL, Slatter DA, Bihan D, Pugh N, et al. OSCAR is a
collagen receptor that costimulates osteoclastogenesis in DAP12-deﬁcient
humans and mice. J Clin Invest 2011.
[8] Herman S, Muller RB, Kronke G, Zwerina J, Redlich K, Hueber AJ, et al. Induction of
osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheu-
matoid arthritis. Arthritis Rheum 2008;58:3041-50.
[9] Kim GS, Koh JM, Chang JS, Park BL, Kim LH, Park EK, et al. Association of the OSCAR
promoter polymorphism with BMD in postmenopausal women. J Bone Miner Res
2005;20:1342-8.
[10] Goettsch C, Rauner M, Sinningen K, Helas S, Al-Fakhri N, Nemeth K, et al. The
osteoclast-associated receptor (OSCAR) is a novel receptor regulated by oxidized
low-density lipoprotein in human endothelial cells. Endocrinology 2011;152:4915-26.
[11] Hilger M, Bonaldi T, Gnad F, Mann M. Systems-wide analysis of a phosphatase
knock-down by quantitative proteomics and phosphoproteomics. Mol Cell Prote-
omics 2009;8:1908-20.
[12] Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al. Stable
isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate ap-
proach to expression proteomics. Mol Cell Proteomics 2002;1:376-86.
[13] Ades EW, Hierholzer JC, George V, Black J, Candal F. Viral susceptibility of an immor-
talized human microvascular endothelial cell line. J Virol Methods 1992;39:83-90.
[14] Mueller LN, Brusniak MY, Mani DR, Aebersold R. An assessment of software solu-
tions for the analysis of mass spectrometry based quantitative proteomics data.
J Proteome Res 2008;7:51-61.
[15] Laemmli UK. Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 1970;227:680-5.
[16] Muller SA, Kohajda T, Findeiss S, Stadler PF, Washietl S, Kellis M, et al. Optimiza-
tion of parameters for coverage of low molecular weight proteins. Anal Bioanal
Chem 2010;398:2867-81.
[17] Cox J, Mann M. MaxQuant enables high peptide identiﬁcation rates, individual-
ized p.p.b.-range mass accuracies and proteome-wide protein quantiﬁcation.
Nat Biotechnol 2008;26:1367-72.
[18] Cox J, Matic I, Hilger M, Nagaraj N, Selbach M, Olsen JV, et al. A practical guide to
the MaxQuant computational platform for SILAC-based quantitative proteomics.
Nat Protoc 2009;4:698-705.
[19] Merck E, Gaillard C, Gorman DM, Montero-Julian F, Durand I, Zurawski SM, et al.
OSCAR is an FcRγ-associated receptor that is expressed by myeloid cells and is in-
volved in antigen presentation and activation of human dendritic cells. Blood
2004;104:1386-95.
[20] Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk among Jak-STAT, Toll-like receptor,
and ITAM-dependent pathways in macrophage activation. J Leukoc Biol
2007;82:237-43.
837C. Goettsch et al. / Journal of Molecular and Cellular Cardiology 53 (2012) 829–837[21] Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nat
Immunol 2009;10:340-7.
[22] Kim K, Lee J, Kim JH, Jin HM, Zhou B, Lee SY, et al. Protein inhibitor of activated
STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and
osteoclast-associated receptor. J Immunol 2007;178:5588-94.
[23] Lee YJ, Benveniste EN. Stat1 alpha expression is involved in IFN-gamma induction
of the class II transactivator and class II MHC genes. J Immunol 1996;157:1559-68.
[24] Kim JH, Kim K, Youn BU, Jin HM, Kim N. MHC class II transactivator negatively reg-
ulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and
OSCAR. Cell Signal 2010;22:1341-9.
[25] Ho HH, Ivashkiv LB. Role of STAT3 in type I interferon responses. J Biol Chem
2006;281:14111-8.
[26] O'Shea JJ, Murray PJ. Cytokine signaling modules in inﬂammatory responses. Im-
munity 2008;28:477-87.
[27] Huang A, Zhang Y-Y, Chen K, Hatakeyama K, Keaney JF. Cytokine-stimulated GTP
cyclohydrolase I expression in endothelial cells requires coordinated activation of
nuclear factor-κB and Stat1/Stat3. Circ Res 2005;96:164-71.
[28] Wincewicz A, Sulkowska M, Rutkowski R, Sulkowski S, Musiatowicz B, Hirnle T,
et al. STAT1 and STAT3 as intracellular regulators of vascular remodeling. Eur J Intern
Med 2007;18:267-71.
[29] Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regenera-
tion. Nature 2008;453:314-21.
[30] Masri FA, XuW, Comhair SAA, Asosingh K, KooM, Vasanji A, et al. Hyperproliferative
apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension.
Am J Physiol Lung Cell Mol Physiol 2007;293:L548-54.
[31] Miller AM, Wang H, Park O, Horiguchi N, Lafdil F, Mukhopadhyay P, et al.
Anti-inﬂammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic
liver injury. Alcohol Clin Exp Res 2010;34:719-25.
[32] Jung DY, Lee H, Suk K. Pro-apoptotic activity of N-myc in activation-induced cell
death of microglia. J Neurochem 2005;94:249-56.
[33] Auger JM, KuijpersMJ, Senis YA,Watson SP, Heemskerk JW. Adhesion of human and
mouse platelets to collagen under shear: a unifying model. FASEB J 2005;19:825-7.[34] Judware R, Culp LA. N-myc over-expression downregulates alpha 3 beta 1 integrin ex-
pression in human Saos-2 osteosarcoma cells. Clin Exp Metastasis 1997;15:228-38.
[35] Tanaka N, Fukuzawa M. MYCN downregulates integrin alpha 1 to promote inva-
sion of human neuroblastoma cells. Int J Oncol 2008;33:815-21.
[36] Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler
Thromb Vasc Biol 2007;27:2292-301.
[37] Merck E, Gaillard C, Scuiller M, Scapini P, Cassatella MA, Trinchieri G, et al. Ligation
of the FcR gamma chain-associated human osteoclast-associated receptor enhances
the proinﬂammatory responses of human monocytes and neutrophils. J Immunol
2006;176:3149-56.
[38] Merck E, Gaillard C, Gorman DM, Montero-Julian F, Durand I, Zurawski SM, et al.
OSCAR is an FcR gamma-associated receptor that is expressed by myeloid cells
and is involved in antigen presentation and activation of human dendritic cells.
Blood 2004;104:1386-95.
[39] Merck E, de Saint-Vis B, Scuiller M, Gaillard C, Caux C, Trinchieri G, et al. Fc recep-
tor gamma-chain activation via hOSCAR induces survival and maturation of den-
dritic cells and modulates Toll-like receptor responses. Blood 2005;105:3623-32.
[40] Devaraj S, Davis B, Simon SI, Jialal I. CRP promotes monocyte-endothelial cell ad-
hesion via Fcγ receptors in human aortic endothelial cells under static and shear
ﬂow conditions. Am J Physiol Heart Circ Physiol 2006;291:H1170-6.
[41] Hernández-Vargas P, Ortiz-Muñoz G, López-Franco O, Suzuki Y, Gallego-Delgado
J, Sanjuán G, et al. Fcγ receptor deﬁciency confers protection against atherosclero-
sis in apolipoprotein E knockout mice. Circ Res 2006;99:1188-96.
[42] Riegel A-K, Faigle M, Zug S, Rosenberger P, Robaye B, Boeynaems J-M, et al. Selec-
tive induction of endothelial P2Y6 nucleotide receptor promotes vascular inﬂam-
mation. Blood 2011;117:2548-55.
[43] Goettsch C, Goettsch W, Brux M, Haschke C, Brunssen C, Muller G, et al. Arterial
ﬂow reduces oxidative stress via an antioxidant response element and Oct-1
binding site within the NADPH oxidase 4 promoter in endothelial cells. Basic
Res Cardiol 2011;106:551-61.
[44] Goettsch C, Goettsch W, Arsov A, Hofbauer LC, Bornstein SR, Morawietz H. Long-term
cyclic strain downregulates endothelial Nox4. Antioxid Redox Signal 2009;11:2385-97.
